Sandeep P Khot1, Arielle P Davis1, Deborah A Crane2, Patricia M Tanzi1, Denise Li Lue2, Edward S Claflin3, Kyra J Becker1, W T Longstreth1, Nathaniel F Watson1, Martha E Billings4. 1. Department of Neurology, Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA. 2. Department of Physical Medicine and Rehabilitation, Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA. 3. Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI. 4. Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA.
Abstract
STUDY OBJECTIVES:Obstructive sleep apnea (OSA) predicts poor functional outcome after stroke and increases the risk for recurrent stroke. Less is known about continuous positive airway pressure (CPAP) treatment on stroke recovery. METHODS: In a pilot randomized, double-blind, sham-controlled trial, adult stroke rehabilitation patients were assigned to auto-titrating or sham CPAP without diagnostic testing for OSA. Change in Functional Independence Measure (FIM), a measure of disability, was assessed between rehabilitation admission and discharge. RESULTS: Over 18 months, 40 patients were enrolled and 10 withdrew from the study: 7 from active and 3 from sham CPAP (p > 0.10). For the remaining 30 patients, median duration of CPAP use was 14 days. Average CPAP use was 3.7 h/night, with at least 4 h nightly use among 15 patients. Adherence was not influenced by treatment assignment or stroke severity. In intention-to-treat analyses (n = 40), the median change in FIM favored active CPAP over sham but did not reach statistical significance (34 versus 26, p = 0.25), except for the cognitive component (6 versus 2.5, p = 0.04). The on-treatment analyses (n = 30) yielded similar results (total FIM: 32 versus 26, p = 0.11; cognitive FIM: 6 versus 2, p = 0.06). CONCLUSIONS: A sham-controlled CPAP trial among stroke rehabilitation patients was feasible in terms of recruitment, treatment without diagnostic testing and adequate blinding-though was limited by study retention and CPAP adherence. Despite these limitations, a trend towards a benefit of CPAP on recovery was evident. Tolerance and adherence must be improved before the full benefits of CPAP on recovery can be assessed in larger trials.
RCT Entities:
STUDY OBJECTIVES: Obstructive sleep apnea (OSA) predicts poor functional outcome after stroke and increases the risk for recurrent stroke. Less is known about continuous positive airway pressure (CPAP) treatment on stroke recovery. METHODS: In a pilot randomized, double-blind, sham-controlled trial, adult stroke rehabilitation patients were assigned to auto-titrating or sham CPAP without diagnostic testing for OSA. Change in Functional Independence Measure (FIM), a measure of disability, was assessed between rehabilitation admission and discharge. RESULTS: Over 18 months, 40 patients were enrolled and 10 withdrew from the study: 7 from active and 3 from sham CPAP (p > 0.10). For the remaining 30 patients, median duration of CPAP use was 14 days. Average CPAP use was 3.7 h/night, with at least 4 h nightly use among 15 patients. Adherence was not influenced by treatment assignment or stroke severity. In intention-to-treat analyses (n = 40), the median change in FIM favored active CPAP over sham but did not reach statistical significance (34 versus 26, p = 0.25), except for the cognitive component (6 versus 2.5, p = 0.04). The on-treatment analyses (n = 30) yielded similar results (total FIM: 32 versus 26, p = 0.11; cognitive FIM: 6 versus 2, p = 0.06). CONCLUSIONS: A sham-controlled CPAP trial among stroke rehabilitation patients was feasible in terms of recruitment, treatment without diagnostic testing and adequate blinding-though was limited by study retention and CPAP adherence. Despite these limitations, a trend towards a benefit of CPAP on recovery was evident. Tolerance and adherence must be improved before the full benefits of CPAP on recovery can be assessed in larger trials.
Authors: Justine A Aaronson; Coen A M van Bennekom; Winni F Hofman; Tijs van Bezeij; Joost G van den Aardweg; Erny Groet; Wytske A Kylstra; Ben Schmand Journal: Sleep Date: 2015-09-01 Impact factor: 5.849
Authors: Michael Arzt; Terry Young; Laurel Finn; James B Skatrud; T Douglas Bradley Journal: Am J Respir Crit Care Med Date: 2005-09-01 Impact factor: 21.405
Authors: Martha E Billings; Dennis Auckley; Ruth Benca; Nancy Foldvary-Schaefer; Conrad Iber; Susan Redline; Carol L Rosen; Phyllis Zee; Vishesh K Kapur Journal: Sleep Date: 2011-12-01 Impact factor: 5.849
Authors: Lianne M Tomfohr; Thomas Hemmen; Loki Natarajan; Sonia Ancoli-Israel; Jose S Loredo; Robert K Heaton; Wayne Bardwell; Paul J Mills; Roland R Lee; Joel E Dimsdale Journal: Stroke Date: 2012-09-27 Impact factor: 7.914
Authors: Marianne Beninato; Kathleen M Gill-Body; Sara Salles; Paul C Stark; Randie M Black-Schaffer; Joel Stein Journal: Arch Phys Med Rehabil Date: 2006-01 Impact factor: 3.966
Authors: Nancy A Collop; W McDowell Anderson; Brian Boehlecke; David Claman; Rochelle Goldberg; Daniel J Gottlieb; David Hudgel; Michael Sateia; Richard Schwab Journal: J Clin Sleep Med Date: 2007-12-15 Impact factor: 4.062
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Michelle L Reid; Kevin J Gleason; Jessie P Bakker; Rui Wang; Murray A Mittleman; Susan Redline Journal: Sleep Date: 2019-08-01 Impact factor: 5.849